1
|
Eker N, Tokuç G, Sarısaltık A, Dağçınar A, Gül D, Atasoy BM, Yılmaz B, Taş BT. Clinical factors, management, and outcomes of children under 3 years old with central nervous system tumors: single-center experience. Childs Nerv Syst 2024:10.1007/s00381-024-06386-9. [PMID: 38619586 DOI: 10.1007/s00381-024-06386-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Accepted: 04/02/2024] [Indexed: 04/16/2024]
Abstract
PURPOSE Children under 3 years old represent a notable portion, about 25 to 30%, of all central nervous system tumor (CNS) cases. Their clinical course, prognosis, and treatment significantly differ from older children. This single-center retrospective study aims to comprehensively analyze survival factors in children under three diagnosed with CNS tumors. METHODS Between April 2012 and December 2023, cases under 3 years of age with CNS tumors diagnosed at our center were retrospectively evaluated. RESULTS Among 279 CNS tumor cases, 42 (15%) were evaluated. The 5-year overall and event-free survival rates were 67.4% (95% CI 47.5-81.1) and 39.8% (95% CI 24.2-55.0), respectively. Gender, symptom onset to diagnosis time, pathological neurological findings at diagnosis, and tumor location did not significantly impact survival (p > 0.05). However, cases with neurological symptoms showed significantly higher event-free survival rates (p < 0.05). Patients with embryonal tumors, metastases, inability for total surgical excision, relapsed/progressive diseases, and who under 1 year old had significantly lower survival rates (p < 0.05). Radiotherapy timing did not affect survival (p > 0.05). Event-free survival rates remained unchanged after the third year. CONCLUSION The current treatments have been observed to have a positive impact on survival rates. Nonetheless, there is a need for novel treatments for patients with embryonal tumors, metastases, aged under 1 year, and those where total surgical excision is not feasible or in cases with progressive/relapse disease. This study underscores the importance of the first 3 years regarding relapse, progression, or mortality risk.
Collapse
Affiliation(s)
- Nurşah Eker
- Department of Pediatric Hematology Oncology, Marmara University, Marmara Faculty of Medicine, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey.
| | - Gülnur Tokuç
- Department of Pediatric Hematology Oncology, Marmara University, Marmara Faculty of Medicine, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey
| | - Alican Sarısaltık
- Republic of Turkey Ministry of Health, Cayırova District Health Directorate, Kocaeli, Turkey
| | - Adnan Dağçınar
- Department of Neurosurgery, Marmara University, Marmara Faculty of Medicine, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey
| | - Dilek Gül
- Department of Radiation Oncology, Marmara University, Marmara Faculty of Medicine, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey
| | - Beste Melek Atasoy
- Department of Radiation Oncology, Marmara University, Marmara Faculty of Medicine, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey
| | - Barış Yılmaz
- Department of Pediatric Hematology Oncology, Pendik Education and Research Hospital, Marmara University, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey
| | - Burcu Tufan Taş
- Department of Pediatric Hematology Oncology, Pendik Education and Research Hospital, Marmara University, Fevzi Çakmak Mah, 34899, Pendik, Istanbul, Turkey
| |
Collapse
|
2
|
Kebudi R, Kurucu N, Tuğcu D, Hacısalihoğlu Ş, Fışgın T, Ocak S, Tokuç G, Nihal Özdemir G, Bozkurt C, İnce D, Aras S, Ayçiçek A, Aksoy BA, Karadaş N, Öztürk G, Orhan MF, Ataseven E, Akbayram S, Yılmaz E, Tüfekçi Ö, Vural S, Akyay A, Ayhan AC, Kılıç S, Uzel VH, Düzenli Y, Kazancı EG, Acıpayam C, Elli M, Tanyeli A, Karakas Z, Somer A, Kara A. COVID-19 infection in children with cancer and stem cell transplant recipients in Turkey: A nationwide study. Pediatr Blood Cancer 2021; 68:e28915. [PMID: 33538100 PMCID: PMC7995085 DOI: 10.1002/pbc.28915] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Revised: 12/19/2020] [Accepted: 01/07/2021] [Indexed: 01/08/2023]
Affiliation(s)
- Rejin Kebudi
- Pediatric Hematology‐OncologyInstitute of OncologyIstanbul UniversityIstanbulTurkey
| | - Nilgün Kurucu
- Department of Pediatric OncologyCancer InstituteHacettepe University Faculty of MedicineAnkaraTurkey
| | - Deniz Tuğcu
- Department of Pediatric Hematology‐Oncologyİstanbul University Faculty of MedicineIstanbulTurkey
| | - Şadan Hacısalihoğlu
- Department of Pediatric Hematology‐OncologySağlık Bilimleri University Kanuni Sultan Süleyman Training and Research HospitalIstanbulTurkey
| | - Tunç Fışgın
- Department of Pediatric Hematology Pediatric Stem Cell TransplantationAltınbaş University Medical Park HospitalIstanbulTurkey
| | - Süheyla Ocak
- Department of Pediatric Hematology‐OncologyCerrahpaşa University Faculty of MedicineIstanbulTurkey
| | - Gülnur Tokuç
- Department of Pediatric OncologyMarmara University Faculty of MedicineIstanbulTurkey
| | - Gül Nihal Özdemir
- Department of Pediatric Hematology‐OncologySağlık Bilimleri University Kanuni Sultan Süleyman Training and Research HospitalIstanbulTurkey
| | - Ceyhun Bozkurt
- Department of Pediatric Hematology Pediatric Stem Cell TransplantationAltınbaş University Medical Park HospitalIstanbulTurkey
| | - Dilek İnce
- Department of Pediatric OncologyDokuz Eylül University Faculty of MedicineİzmirTurkey
| | - Seda Aras
- Department of Pediatric OncologyMarmara University Faculty of MedicineIstanbulTurkey
| | - Ali Ayçiçek
- Department of Pediatric Hematology‐OncologySağlık Bilimleri University Kanuni Sultan Süleyman Training and Research HospitalIstanbulTurkey
| | - Başak Adaklı Aksoy
- Department of Pediatric Hematology Pediatric Stem Cell TransplantationAltınbaş University Medical Park HospitalIstanbulTurkey
| | - Nihal Karadaş
- Department of Pediatric HematologyEge University Faculty of MedicineİzmirTurkey
| | - Gülyüz Öztürk
- Department of Pediatric Hematology and Pediatric Stem Cell TransplantationAcıbadem Altunizade HospitalIstanbulTurkey
| | - Mehmet Fatih Orhan
- Department of Pediatric Hematology‐OncologySakarya University Faculty of MedicineSerdivanTurkey
| | - Eda Ataseven
- Department of Pediatric OncologyEge University Faculty of MedicineİzmirTurkey
| | - Sinan Akbayram
- Department of Pediatric Hematology‐OncologyGaziantep University Faculty of MedicineGaziantepTurkey
| | - Ebru Yılmaz
- Department of Pediatric Hematology‐OncologyErciyes University Faculty of MedicineKayseriTurkey
| | - Özlem Tüfekçi
- Department of Pediatric HematologyDokuz Eylül University Faculty of MedicineİzmirTurkey
| | - Sema Vural
- Department of Pediatric OncologySağlık Bilimleri University Hamidiye Şişli Etfal Training and Research HospitalIstanbulTurkey
| | - Arzu Akyay
- Department of Pediatric Hematology‐Oncologyİnönü University Faculty of MedicineMalatyaTurkey
| | - Aylin Canbolat Ayhan
- Department of Pediatric Hematologyİstanbul Medeniyet University Faculty of MedicineIstanbulTurkey
| | - Suar Kılıç
- Department of Pediatric Hematology‐OncologySağlık Bilimleri University Ümraniye Training and Research HospitalIstanbulTurkey
| | - Veysiye Hülya Uzel
- Department of Pediatric Hematology‐OncologyDicle University Faculty of MedicineTurkey
| | - Yeter Düzenli
- Department of Pediatric Hematology‐OncologySağlık Bakanlığı Erzurum Training and Research HospitalErzurumTurkey
| | - Elif Güler Kazancı
- Department of Pediatric Hematology‐OncologySağlık Bilimleri University Bursa Yüksek İhtisas Training and Research HospitalBursaTurkey
| | - Can Acıpayam
- Department of Pediatric Hematolology‐OncologyKahramanmaraş Sütçü İmam University Faculty of MedicineKahramanmaraşTurkey
| | - Murat Elli
- Department of Pediatric Hematology‐Oncology and Bone Marrow Transplantationİstanbul Medipol UniversityIstanbulTurkey
| | - Atilla Tanyeli
- Department of Pediatric Stem Cell TransplantationMemorial Şişli HospitalIstanbulTurkey
| | - Zeynep Karakas
- Department of Pediatric Hematology‐Oncologyİstanbul University Faculty of MedicineIstanbulTurkey
| | - Ayper Somer
- Department of Pediatric Infectious Diseaseİstanbul University Faculty of MedicineIstanbulTurkey
| | - Ateş Kara
- Department of Pediatric Infectious DiseaseHacettepe University Faculty of MedicineAnkaraTurkey
| |
Collapse
|
3
|
Karadeniz Cerit K, Cerit C, Nart Ö, Eker N, Kıyan G, Dağlı T, Ekingen G, Tokuç G, Karaca Ö, Çorapçıoğlu F. Post-traumatic stress disorder in mothers of children who have undergone cancer surgery. Pediatr Int 2017; 59:996-1001. [PMID: 28613013 DOI: 10.1111/ped.13343] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Revised: 05/05/2017] [Accepted: 06/08/2017] [Indexed: 11/27/2022]
Abstract
BACKGROUND The aim of this study was to investigate the rate of post-traumatic stress disorder (PTSD) and associated risk factors among mothers of children who underwent cancer surgery. METHOD This cross-sectional, multi-center study included a total of 60 mothers whose children underwent major thoraco-abdominal surgery and were under follow up in the outpatient setting between February 2016 and May 2016. Clinical Data Form, Hospital Anxiety and Depression Scale (HADS), and Clinician-Administered PTSD scale were used. RESULTS Of all participants, 13 (21.7%) were diagnosed with PTSD. These mothers had shorter duration of marriage, longer duration of hospital stay after surgery, and higher HADS scores, compared with the others without PTSD. Thoughts of guilt such as "I am being punished or tested" were more frequent in mothers with PTSD. Insomnia, irritability, concentration problems, and psychological reactivity were the most common symptoms. CONCLUSION Post-traumatic stress disorder is a severe disorder that may worsen the daily functioning of mothers and may also have an unfavorable effect on child. It is therefore of utmost importance for clinicians to recognize PTSD and the associated risk factors in order to guide these parents.
Collapse
Affiliation(s)
| | - Cem Cerit
- Department of Psychiatry, School of Medicine, Kocaeli University, Izmit, Kocaeli, Turkey
| | - Ömer Nart
- Department of Psychiatry, School of Medicine, Kocaeli University, Izmit, Kocaeli, Turkey
| | - Nurşah Eker
- Department of Pediatric Oncology, School of Medicine, Marmara University, Istanbul, Turkey
| | - Gürsu Kıyan
- Department of Pediatric Surgery, School of Medicine, Marmara University, Istanbul, Turkey
| | - Tolga Dağlı
- Department of Pediatric Surgery, School of Medicine, Marmara University, Istanbul, Turkey
| | - Gülşen Ekingen
- Department of Pediatric Surgery, School of Medicine, Kocaeli University, Izmit, Kocaeli, Turkey
| | - Gülnur Tokuç
- Department of Pediatric Oncology, School of Medicine, Marmara University, Istanbul, Turkey
| | - Ömer Karaca
- Department of Pediatric Oncology, School of Medicine, Kocaeli University, Izmit, Kocaeli, Turkey
| | - Funda Çorapçıoğlu
- Department of Pediatric Oncology, School of Medicine, Kocaeli University, Izmit, Kocaeli, Turkey
| |
Collapse
|
4
|
Sirinoglu M, Soysal A, Karaaslan A, Kepenekli Kadayifci E, Cinel I, Koç A, Tokuç G, Yaman A, Haklar G, Şirikçi Ö, Turan S, Altınkanat Gelmez G, Söyletir G, Bakır M. The diagnostic value of soluble urokinase plasminogen activator receptor compared with C-reactive protein and procalcitonin in children with febrile neutropenia. Pediatr Hematol Oncol 2016; 33:200-8. [PMID: 27057782 DOI: 10.3109/08880018.2016.1155100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The aim of the present study was to determine the diagnostic value of soluble urokinase plasminogen activator receptor (suPAR) in pediatric patients with febrile neutropenia. A prospective case-control study was performed. Patients included 29 children with febrile neutropenia (FN) and 27 control subjects without any infection or immunosuppressive condition. Blood samples were obtained on the day of admission and on the 4th to 7th days of the hospital stay. The median (minimum-maximum) serum levels of suPAR obtained on the first day of the admission were 2.08 (0.93-9.42) and 2.22 (1.08-5.13) ng/mL for the FN group and the control group, respectively. The median serum levels of suPAR in the FN and control groups were not significantly different (P = .053). The mean serum suPAR level was significantly higher in nonsurvivors than in survivors in the FN group (P < .05). In the FN group, the area under the receiver operating characteristics curve (AUCROC) for suPAR was 0.546, but no optimum cutoff value, sensitivity, specificity, negative predictive value (NPV), or positive predictive value (PPV) was obtained. We conclude that suPAR is not useful as a diagnostic biomarker in children with febrile neutropenia; however, persistent high serum suPAR level may predict mortality in FN in children.
Collapse
Affiliation(s)
- Melis Sirinoglu
- a Division of Pediatric Infectious Diseasesm, Department of Pediatrics , Marmara University School of Medicine , Istanbul , Turkey
| | - Ahmet Soysal
- a Division of Pediatric Infectious Diseasesm, Department of Pediatrics , Marmara University School of Medicine , Istanbul , Turkey
| | - Ayşe Karaaslan
- a Division of Pediatric Infectious Diseasesm, Department of Pediatrics , Marmara University School of Medicine , Istanbul , Turkey
| | - Eda Kepenekli Kadayifci
- a Division of Pediatric Infectious Diseasesm, Department of Pediatrics , Marmara University School of Medicine , Istanbul , Turkey
| | - Ismail Cinel
- b Department of Anesthesiology and Reanimation , Marmara University School of Medicine , Istanbul , Turkey
| | - Ahmet Koç
- c Division of Hematology and Oncology, Department of Pediatrics , Marmara University School of Medicine , Istanbul , Turkey
| | - Gülnur Tokuç
- c Division of Hematology and Oncology, Department of Pediatrics , Marmara University School of Medicine , Istanbul , Turkey
| | - Ali Yaman
- d Department of Biochemistry , Marmara University School of Medicine , Istanbul , Turkey
| | - Goncagül Haklar
- d Department of Biochemistry , Marmara University School of Medicine , Istanbul , Turkey
| | - Önder Şirikçi
- d Department of Biochemistry , Marmara University School of Medicine , Istanbul , Turkey
| | - Serap Turan
- e Division of Pediatric Endocrinology, Department of Pediatrics , Marmara University School of Medicine , Istanbul , Turkey
| | | | - Güner Söyletir
- f Department of Microbiology , Marmara University School of Medicine , Istanbul , Turkey
| | - Mustafa Bakır
- a Division of Pediatric Infectious Diseasesm, Department of Pediatrics , Marmara University School of Medicine , Istanbul , Turkey
| |
Collapse
|
5
|
Karakaş A, Tutar E, Tokuç G, Öktem S, Boran P. Hepatosplenic Candidiasis with Generalized Cutaneous Nodular Lesions: A Case Report. J Pediatr Inf 2013. [DOI: 10.5152/ced.2013.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
6
|
Akyüz C, Yalçin B, Yildiz I, Hazar V, Yörük A, Tokuç G, Akici F, Büyükpamukçu N, Kale G, Atahan L, Büyükünal C, Dervişoğlu S, Atkovar GA, Melikoğlu M, Karpuzoğlu G, Olgun N, Ayan I, Oğuz A, Yariş N, Dağdemir A, Darendeliler E, Sander S, Kuyumcuoğlu U, Ozşeker N, Corapçioğlu F, Tanyeli A, Düzovali O, Aydin GB, Büyükpamukçu M. Treatment of Wilms tumor: a report from the Turkish Pediatric Oncology Group (TPOG). Pediatr Hematol Oncol 2010; 27:161-78. [PMID: 20367260 DOI: 10.3109/08880010903447375] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
AIM To standardize diagnosis and treatment of childhood Wilms tumor (WT) in Turkey. METHODS AND PATIENTS Between 1998 and 2006, WT patients were registered from 19 centers. Patients <16 years with unilateral WT whose treatment started in first postoperative 3 weeks were included. Treatments were stage I favorable (FH) and unfavorable histology (UH) patients, VCR + Act-D; stage IIA FH, VCR + Act-D; stage IIB FH, VCR + Act-D + radiotherapy (RT); stage III-IV FH, VCR + Act-D + adriamycin (ADR) + RT; stages II-IV UH tumors, VCR + Act-D + ADR + etoposide + RT. RESULTS 165/254 registered cases were eligible (bilateral, 5.9%) [median age 3.0 years; M/F: 0.99; 50/165 cases < or =2 years]. 9.7% cases had UH tumors. Disease stages were stage I 23.6%; IIA 36.4%; IIB 5.5%; III 22.4%; IV 12.1%. Cases >2 years had significantly more advanced disease. 1/11 cases with recurrent disease died; 2/165 had progressive disease, 2/165 had secondary cancers, and all 4 died. In all cases 4-year OS and EFS were 92.8 and 86.5%, respectively. Both OS and EFS were significantly worse in stage IV. CONCLUSIONS Despite problems in patient management and follow-up, treatment results were encouraging in this first national experience with a multicentric study in pediatric oncology. Revisions and modifications are planned to further improve results and minimize short- and long-term side effects.
Collapse
Affiliation(s)
- Canan Akyüz
- Hacettepe University Faculty of Medicine, Dept. of Pediatric Oncology, Ankara, Turkey.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Tokuç G, Minareci O, Yavuzer D, Kiliçkap C, Gökyayla N. Moya Moya syndrome in a child with hyperphosphatasia. Pediatr Int 1999; 41:399-402. [PMID: 10453193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Affiliation(s)
- G Tokuç
- Pediatric Clinic, Kartal Education and Research Hospital, Istanbul, Turkey.
| | | | | | | | | |
Collapse
|
8
|
Tokuç G, Doğan O, Ayan I, Kebudi R, Doğan S, Demiryont M, Camlica H. Prognostic value of proliferating cell nuclear antigen immunostaining in pediatric rhabdomyosarcomas. Acta Paediatr Jpn 1998; 40:573-9. [PMID: 9893293 DOI: 10.1111/j.1442-200x.1998.tb01993.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND The levels of proliferating cell nuclear antigen (PCNA) are almost negligible in long-term quiescent cells and increase dramatically during the cell cycle. Recently, the monoclonal antibodies to PCNA have been used to demonstrate the proliferative component of paraffin-embedded tumor tissues. It has been shown to be available as a simple histological marker of proliferative activity and the PCNA labeling index has been correlated with the prognosis of several malignant neoplasms. METHODS Formalin fixed, paraffin embedded tissue specimens of 29 primary pediatric rhabdomyosarcomas were immunostained by using an anti-PCNA monoclonal antibody (DAKO PCNA PC10). The relationship between the PCNA index and prognosis, clinicopathological features and survival were assessed retrospectively. RESULTS The mean PCNA index for the whole series was 54%. There was no correlation between PCNA index and any of the clinicopathological characteristics. However, patients having tumors with a high (> 54%) PCNA index demonstrated significantly lower survival rates than tumors with a low (< 54%) PCNA index (P = 0.01). Moreover, there were significantly more patients with relapse or progressive disease in the high PCNA index group (P = 0.005). CONCLUSION The PCNA labeling index can be a useful prognostic factor and a good indicator of recurrence and/or survival in patients with rhabdomyosarcoma.
Collapse
Affiliation(s)
- G Tokuç
- Institute of Oncology, Department of Pediatric Oncology, University of Istanbul, Turkey.
| | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
Granulocyte colony-stimulating factor (G-CSF) has been used to reduce the duration and/or degree of neutropenia of different etiologies in recent years. In this study, experience with the use of G-CSF (Neupogen, Roche) after 123 courses of highly myelosuppressive chemotherapy administered to 31 (20 female, 11 male) patients with pediatric solid tumors is reported. G-CSF was initiated at a white blood cell (WBC) count of 918 +/- 452/microL (100-2000), at a dose of 7.6 +/- 2.3 micrograms/kg/d (5-14) subcutaneously for 5.2 +/- 2.4 days (2-18). G-CSF was given for afebrile neutropenia after 82 and for febrile neutropenia after 41 courses. Only in two episodes where G-CSF was given for afebrile neutropenia, fever developed. The average hospitalization period for febrile neutropenia was 9.8 +/- 3.3 days (5-20). Chemotherapy could be given on scheduled time and dosage in 90% of the courses in which G-CSF was used for afebrile neutropenia. G-CSF was well tolerated. Bone pain was observed in two patients and urticaria in one patient. In conclusion, G-CSF increased the WBC count effectively, there were only two febrile episodes in 82 courses in children receiving G-CSF for afebrile neutropenia, it was well tolerated, and it was found to be feasible for use in a developing country.
Collapse
Affiliation(s)
- I Ayan
- Oncology Institute, University of Istanbul, Turkey
| | | | | | | | | |
Collapse
|